Opill®, the first ever daily birth control pill available without a prescription in the United States, will be available in-store and online at retailers nationwide in the coming weeks and for pre-order from select retailers beginning this week   To maximize the impact and accessibility of Opill®, Perrigo has sought to ensure both the affordability and availability of Opill® on shelves across the country and online DUBLIN and GRAND RAPIDS, Mich., March 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRG ...

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS Global Consumer and Retail Conference in New York City on Wednesday, March 13th at 4:00 PM EST.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. About Perrigo  Perrigo Company plc (NYSE: PRGO) is a ...

Perrigo Company plc (PRGO) reported adjusted earnings of 86 cents per share in the fourth quarter of 2023, beating the Zacks Consensus Estimate of 83 cents. Earnings were up 14.7% year over year. The upside can be attributed to lower operating expenses incurred by the company during the quarter.Net sales increased 0.1% year over year to $1.16 billion, missing the Zacks Consensus Estimate of $1.19 billion. The upside was driven by growth stemming from the acquisition of the U.S. & Canadian Good Start infant ...

Financial Data and Key Metrics Changes - Net sales in fiscal 2023 grew nearly 5%, driven by international and core US OTC businesses, with organic net sales increasing 2% [7][29] - Gross margin expanded 260 basis points to 38.8%, and operating margin expanded 130 basis points to 12.3% for the full year [7][30] - Full-year EPS was $2.58, an increase of 25% compared to the prior year, with strong cash flow conversion of 115% [7][31] Business Line Data and Key Metrics Changes - Significant growth was realized in skincare, nutrition, and women's health categories, partially fueled by HRA and Gateway acquisitions [8] - Healthy Lifestyle contributed strong growth, particularly in US smoking cessation products, while cough cold sales in the US grew mid-single digits [8][9] - The infant formula business faced challenges due to evolving regulatory guidelines, impacting overall performance [6][11] Market Data and Key Metrics Changes - Store brand dollar share of US OTC increased by 70 basis points, indicating a shift towards value offerings among consumers [9] - The US OTC business is performing well amid a normalizing consumer environment, with store brands gaining market share from national brands [5][6] Company Strategy and Development Direction - The company is focused on augmenting and strengthening its infant formula business while executing Project Energize to enhance operational efficiency [10][15] - The launch of Opill is seen as a key pillar for growth in women's healthcare, with plans for a comprehensive marketing strategy [20][23] - The company aims to centralize capital allocation decisions and streamline operations to enhance decision-making and simplify commercial operations [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in stabilizing the infant formula business despite current challenges, with expectations for recovery in the second half of 2024 [14][22] - The company anticipates mid-teens EPS growth in 2024, excluding the impact of the infant formula business, which is expected to be flat compared to 2023 [21][33] - Management emphasized the importance of executing remediation plans and enhancing brand-building capabilities to drive future growth [39][41] Other Important Information - The company reported a GAAP net loss of $4 million for 2023, with adjusted net income of $352 million [27] - Cash on the balance sheet increased to $751 million, with expectations for healthy cash flow conversion in 2024 [34][35] - The company plans to pay down $400 million in debt and increase capital investments in the infant formula business [35][36] Q&A Session Summary Question: Expectations for infant formula top line recovery - Management expects the first quarter to be the worst for infant formula, with gradual improvement anticipated throughout the year [46][47] Question: Long-term profitability of the infant formula business - The goal is to return to historical profit levels, with an ambition to achieve around $140 million in operating income [48][49] Question: Rollout plans for Opill - Opill is set for a nationwide rollout with strong retail and online activation plans, expected to generate significant initial revenue [50][51] Question: Confidence in resolving nutritional issues - Management expressed confidence in the remediation efforts, citing previous successful interventions in similar regulated industries [55][56] Question: Competitive landscape and share loss concerns - Management is working closely with retailers to minimize disruption and retain partnerships, emphasizing the importance of quality assurance [59][60] Question: 2025 targets and growth perspectives - Management plans to provide clearer growth perspectives during the Investor Day in the fall, focusing on executing current priorities [61][62]

Perrigo (PRGO) reported $1.16 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.2%. EPS of $0.86 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.19 billion, representing a surprise of -2.51%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Adding HR photos ...

Net Sales from Continuing Operations Were a Fourth Quarter and Fiscal Year Record Delivered Fiscal Year 2023 Double-Digit Improvement in Gross Profit, Operating Income and EPS, Year-Over-Year  Achieved Sixth Consecutive Quarter of Year-Over-Year Gross Margin Expansion Launching 'Project Energize' Investment and Efficiency Program to Drive the Company's One Perrigo Sustainable, Value Accretive Growth Strategy  DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Fourth Quarter 2023 Highlights: Fourth quarter net sales of ...

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, announces that its Board of Directors has approved a 1% increase in the Company's quarterly dividend to $0.276 per share, or $1.10 per share on an annual basis, up from $0.273 per share. This marks the 21st consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 26, 2024, to shareholders of record on March 8, 2024. About Perrigo  Perrigo Company ...

EXHIBIT 99.1 Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program Net Sales from Continuing Operations Were a Fourth Quarter and Fiscal Year Record Delivered Fiscal Year 2023 Double-Digit Improvement in Gross Profit, Operating Income and EPS, Year-Over-Year Achieved Sixth Consecutive Quarter of Year-Over-Year Gross Margin Expansion Launching 'Project Energize' Investment and Efficiency Program to Drive the Company's One Perr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-36353 Perrigo Company plc (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...